PARP inhibitors possess anti‐inflammatory activity and have been reported to have therapeutic potential in a wide range of inflammatory‐ and ischemia–reperfusion‐associated diseases, including cardiovascular diseases, diabetes, rheumatoid arthritis, endotoxic shock, and stroke.33, 34, 35, 36. Here, PARP1 is linked to diabetes mellitus.